Compare Amgen, Inc. (AMGN) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Stanley Black & Decker, Inc. — how do they compare? Amgen, Inc. trades at $356.91 (market cap $196.12B), while Stanley Black & Decker, Inc. trades at $85.95 (market cap $13.71B). The key difference: Amgen, Inc. is far larger — about 14.3× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.76%). Which is the better fit depends on your goals.
| AMGN | SWK | |
|---|---|---|
Market Cap | $196.12B | $13.71B |
Sector | Health | — |
52-Week High | $388.16 | $94.12 |
52-Week Low | $271.18 | $62.12 |
Enterprise Value | $241.41B | $19.88B |
Dividend Yield | 2.77% | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Stanley Black & Decker (SWK) trades at $88.22, up 1.61% with a bullish technical signal and consistent earnings beats. The stock shows strong valuation metrics with P/S of 0.88 and P/B of 1.53, while profitability remains modest with 2.44% net margin. Recent corporate actions include a $0.83 dividend payment, and cash flow trends indicate operational stability despite slight net outflows.
SWK presents a mixed outlook with positive earnings momentum and aerospace/automotive demand offset by Tools & Outdoor segment weakness and elevated debt. Analyst consensus leans neutral (51% Hold) with $82.75 price target below current levels. Key risks include consumer sentiment pressures and high debt load, though cost-saving initiatives support turnaround potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
